MedReader: News

• Rexahn Pharmaceuticals Issued Japanese Patent For Anti-cancer Compound Archexin(R) March 10, 2010
  Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®. "The Japanese patent award is another step forward in the development of one of our lead clinical drug candidates, Archexin," said Dr. Chang Ahn, Rexahn's Chairman and Chief Executive Officer...
• Argos Therapeutics Presents Positive Phase 2 Data Of Its Arcelis™ Personalized Immunotherapy Platform In Metastatic RCC At ASCO GU Symposium March 10, 2010
  Argos Therapeutics announced the presentation of positive data from a Phase 2 trial that evaluated the safety, clinical response and immune response of AGS-003 treatment in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). The data were discussed March 7 in a poster presentation at the ASCO Genitourinary Cancers Symposium. AGS-003 is a product of the Company's Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient's unique tumor burden...
• RepRegen™ Reports Potential Advance In The Repair And Regeneration Of Hard-Tissue, Such As Bone March 9, 2010
  RepRegen™, the 'smart biomaterials' company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone...
• Alzheimer's 'Epidemic' Hitting Minorities Hardest (HealthDay) March 9, 2010
  HealthDay - TUESDAY, March 9 (HealthDay News) -- Over 5 million Americans are living with Alzheimer's disease, and blacks and Hispanics are at highest risk of developing the disease, a new report finds.
• Clinical Trials Update: March 9, 2010 (HealthDay) March 9, 2010
  HealthDay - (HealthDay News) -- Here are the latest clinical trials, courtesy of ClinicalConnection.com:
• Obese Colon Cancer Survivors Face Poorer Prognosis (HealthDay) March 9, 2010
  HealthDay - TUESDAY, March 9 (HealthDay News) -- Colon cancer survivors who are moderately or severely obese face tougher survival odds following treatment compared with their normal-weight peers, a new study reveals.
• Kids Who Get Flu Shots Protect the Unvaccinated (HealthDay) March 9, 2010
  HealthDay - TUESDAY, March 9 (HealthDay News) -- Children who get a flu shot help prevent flu from spreading in their communities, Canadian researchers say.
• As You Age, Better Health Means Better Sex (HealthDay) March 9, 2010
  HealthDay - TUESDAY, March 9 (HealthDay News) -- Better health translates into better sex lives, with healthy people more likely to engage in sex (and good sex at that) and to express an interest in sex, new research finds.
• FDA Clears biospace med's SterEOS 2D/3D Workstation For Pediatric Use In Spine March 9, 2010
  biospace med announced today that it has received 510(k) clearance from the FDA (Food and Drug Administration) to market the Company's sterEOS 2D/3D workstation for pediatric use in spine applications. The Company's EOS ultra-low-dose imager previously has been FDA-cleared for use in pediatrics and adults, while sterEOS has previously been FDA-cleared for adult use in spine...
• New Genetic Test Helps Doctors Predict Frequency Of Genital Herpes Outbreaks March 9, 2010
  Molecular dermatology research and development innovator DermaGenoma, Inc. released The HerpesDX Genetic Test for Frequent Genital Herpes. The new screening test will help doctors assess patients' risk for developing frequent Genital Herpes (HSV-2) outbreaks. "Until now, physicians have been unable to give patients an answer to the most common question asked by recently infected Genital Herpes patients: Will I have frequent outbreaks?," says DermaGenoma CEO Andy Goren. "Using the HerpesDX genetic test, a doctor can finally assess a patient's risk for frequent outbreaks...